Skip to content
Main Navigation
About us
Company profile
Our values
Our strategy
Board of Directors
Senior management
Our history
Research and development
Technology platform
Therapeutic areas
Pipeline
Scientific papers and presentations
Partnering
Our approach
Our partnerships
Investors
Financial reports and presentations
Share information
Analyst coverage
Major shareholders
Financial calendar
Corporate governance
Corporate governance statements
Dividend policy
Annual general meeting
Articles of association
Safe harbour statement
Whistleblower policy
Risk management
Investor relations policy
ESG
Email alerts
Media
News and announcements
Image library
Glossary
Email alerts
Careers
Life at Nykode
Meet us
Open positions
Search
Media
News and Announcements
Newest first
Oldest first
Announcements
News
Search
Reset
07/05/2019
VACCIBODY CALLS FOR ANNUAL GENERAL MEETING – MAY 2019
01/04/2019
VACCIBODY AS AND NEKTAR THERAPEUTICS PRESENT NEW PRECLINICAL DATA FROM THEIR IMMUNO-ONCOLOGY COLLABORATION AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2019
25/03/2019
POSITIVE 12-MONTH RESULTS FROM PHASE IIa CLINICAL STUDY IN HIGH GRADE CERVICAL DYSPLASIA PROVIDES PROOF-OF-CONCEPT FOR VACCIBODY’S IMMUNOTHERAPY PLATFORM AND LEAD CANDIDATE VB1O.16
27/02/2019
VACCIBODY AS TO PRESENT DATA ON VB10.NEO AND VB10.16 AT UPCOMING AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING
14/02/2019
VACCIBODY AS – NOK 230 MILLION (EUR 23.6 MILLION) PRIVATE PLACEMENT SUCCESSFULLY PLACED
Pages:
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
Load more
Sorry, nothing found in this query
Privacy statement
Cookie policy
Disclaimer